Key takeaway
Among 3844 US postmenopausal women followed a median of 119 months, TyG-BMI had a U-shaped link with death from any cause, with a turning point near 289: below it, each 1 SD rise went with HR 0.77, above it HR 1.28. It is an observational cohort with a single baseline measurement, so low and high values may reflect other health differences.
Study design
Cohort study
Reading basis
Published abstract
Reading focus
Association & confounding
The research question
The triglyceride-glucose body mass index (TyG-BMI) combines a marker of insulin resistance with body size, and it is unclear how it relates to long-term death risk after menopause, when metabolism shifts. The authors tested its link with death from any cause, and with cardiovascular and cancer deaths, in a nationally representative US sample.
Who and how
Retrospective cohort analysis of 3844 postmenopausal women (mean age 64.8 ± 10.8 years) from NHANES 2001-2014 with fasting triglycerides, glucose and BMI measured at baseline. TyG-BMI was calculated as ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2] × BMI. Deaths were identified through the National Death Index, with median follow-up of 119 months (about 9.9 years). Cox models estimated hazard ratios (HR) per standard deviation (SD) increase, adjusted for age, ethnicity, poverty-income ratio, smoking, alcohol use and total physical activity. Restricted cubic splines and a two-piece Cox model tested nonlinearity and thresholds, with sensitivity analyses.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1During follow-up, 1033 women (26.9%) died, including 336 cardiovascular deaths (8.7%). Mean baseline TyG-BMI was 260.7 ± 67.0.
- 2The relationship with all-cause mortality was U-shaped (P < 0.0001 for nonlinearity) with an inflection point near 289.
- 3Below 289, each 1 SD (67.0-unit) rise was linked to lower mortality (adjusted HR 0.77, 95% CI 0.69-0.86, P < 0.0001). Above 289, each SD rise was linked to higher mortality (HR 1.28, 95% CI 1.13-1.46, P = 0.0002).
- 4Cardiovascular mortality showed a similar U-shape but with less precise estimates because of fewer events. Cancer mortality showed no significant association; higher TyG-BMI tended toward slightly lower risk, not significantly.
- 5Results were consistent in sensitivity analyses.
Limits & uncertainty
- 1TyG-BMI was measured once at baseline, so changes in weight, lipids or glucose over the roughly 10 years are not captured.
- 2The low-end association may reflect illness-related weight loss or frailty (reverse causation), which the abstract does not report excluding, and adjustment did not include diet or medication use.
- 3Cardiovascular estimates were imprecise and the abstract gives no figures for cancer deaths or for the cardiovascular analysis.
- 4The turning point near 289 comes from this one dataset and needs confirmation, and this reading is based on the abstract only.
What to take from it
In this cohort, women with middle TyG-BMI values had the lowest risk of death, while very low and high values carried higher risk. That does not show that raising a low value or lowering a high one would change survival. Glucose, lipid and weight results should be interpreted with a clinician.
Reading your own data
TyG-BMI needs fasting blood triglycerides and glucose from a lab plus weight and height, so it cannot be taken from a wearable alone. If you have lab results, you could compare your own values over time at the same lab and fasting conditions, but do not treat the 289 cut-off as a personal target.
How to read this evidence
Exposure precedes follow-up outcomes, but confounding and reverse causation can remain. A hazard ratio is not an individual absolute risk or a demonstrated intervention effect.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
The triglyceride-glucose body mass index (TyG-BMI) is a novel indicator combining an insulin resistance proxy (TyG index) with adiposity. It remains unclear how TyG-BMI relates to long-term mortality risk in postmenopausal women, a group prone to metabolic changes after menopause. This study investigated the association between TyG-BMI and all-cause mortality, with secondary outcomes of cardiovascular disease (CVD) mortality and cancer mortality, in a nationally representative cohort of US postmenopausal women.
Methods
We analyzed data from 3844 postmenopausal women (mean age 64.8 ± 10.8 years) in the 2001-2014 National Health and Nutrition Examination Survey (NHANES) who had baseline fasting triglycerides, glucose, and body mass index (BMI) measured. The TyG-BMI index was calculated as ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2] × BMI (kg/m^(2)). Mortality outcomes (all-cause, CVD, and cancer mortality) were ascertained through linkage to National Death Index records, with median follow-up of 119 months (approximately 9.9 years). Cox proportional hazards models were used to estimate hazard ratios (HRs) for mortality per standard deviation (SD) increase in TyG-BMI, adjusting for age, ethnicity, poverty-income ratio, smoking, alcohol use, and total physical activity (MET-min/week). We used restricted cubic splines to assess nonlinearity and a two-piece Cox model to estimate threshold effects, with log-likelihood ratio tests to confirm nonlinear associations. Sensitivity analyses were conducted to test the robustness of findings.
Results
Over follow-up, 1033 participants died (26.9%), including 336 CVD deaths (8.7%) and a similar order of magnitude of cancer deaths. The baseline TyG-BMI averaged 260.7 ± 67.0. We observed a nonlinear (U-shaped) relationship between TyG-BMI and all-cause mortality (P < 0.0001 for nonlinearity). An inflection point was identified at a TyG-BMI of approximately 289. Below this point, higher TyG-BMI was associated with lower mortality risk: for each 1 SD (67.0-unit) increase in TyG-BMI, the adjusted HR for all-cause mortality was 0.77 (95% confidence interval [CI] 0.69-0.86, P < 0.0001). Above the threshold of 289, higher TyG-BMI was associated with higher mortality risk: per SD increase HR = 1.28 (95% CI 1.13-1.46, P = 0.0002). In secondary outcome analyses, TyG-BMI showed a similar nonlinear pattern with CVD mortality (U-shaped association, with low TyG-BMI linked to higher CVD death risk and an increasing hazard at the upper end), although estimates were less precise due to fewer events. By contrast, no significant positive association was observed between TyG-BMI and cancer mortality; if anything, higher TyG-BMI tended to correspond to a slight reduction in cancer mortality risk, although this trend did not reach statistical significance. All results were consistent in sensitivity analyses.
Conclusion
In this cohort of US postmenopausal women, TyG-BMI exhibited a U-shaped association with all-cause mortality. Both low and high TyG-BMI values conferred elevated mortality risk, especially from cardiovascular causes, while intermediate TyG-BMI levels were associated with the lowest risk. These findings suggest that maintaining a balanced TyG-BMI, reflecting neither extreme leanness with low metabolic reserves nor excessive insulin-resistant adiposity, might be important for longevity in older women.
Sources & attribution
Nonlinear association of triglyceride-glucose body mass index with all-cause mortality in postmenopausal women, a retrospective cohort study: Evidence from the 2001 to 2014 National Health and nutrition examination survey.
Wang X, Wang K, Tan C, Yu Y.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025-12-31
DOI: 10.1002/ijgo.70778 ↗PubMed · 41476383 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

